Company / Free Cash Flow per Share
Denali Therapeutics Inc. Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$2.93
FY2025
5-year range
-$2.93 / $3.38
FY2021-FY2025
Trend
-11.4%
vs FY2024
Sector context
#149 of 192
Health Care
What the data says
Denali Therapeutics Inc.'s free cash flow per share of $-2.93 is lower than 78% of companies in the Health Care sector (FY2025). Free Cash Flow per Share has fluctuated over the past 10 years, ranging from $-12.15 in FY2016 to $3.38 in FY2022.
Based on SEC 10-K filings.
-2.93 in FY2025.
Declined from $-2.73 to $-2.93 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 192This company -$2.93 Sector average $3.32
▼
-188.2% below sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 11.4% year-over-year.
- Ranks #149 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2022.
- Lowest free cash flow per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.93 | -11.4% |
| FY2024 | -$2.63 | +3.7% |
| FY2023 | -$2.73 | -180.8% |
| FY2022 | $3.38 | +340.2% |
| FY2021 | -$1.41 | -389.5% |
| FY2020 | $0.49 | +157.8% |
| FY2019 | -$0.84 | +5.8% |
| FY2018 | -$0.89 | +83.2% |
| FY2017 | -$5.31 | +56.3% |
| FY2016 | -$12.15 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026